{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:15:28Z","timestamp":1780319728763,"version":"3.54.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00059-021-05035-0","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T11:09:46Z","timestamp":1619694586000},"page":"293-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sekund\u00e4rpr\u00e4vention nach TIA oder isch\u00e4mischem Schlaganfall","Secondary stroke prevention after TIA or ischemic stroke"],"prefix":"10.1007","volume":"46","author":[{"given":"Hans Christoph","family":"Diener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Nickenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"5035_CR1","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/bmj.37991.635266.44","volume":"328","author":"AJ Coull","year":"2004","unstructured":"Coull\u00a0AJ, Lovett\u00a0JK, Rothwell\u00a0PM et\u00a0al (2004) Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328:326","journal-title":"BMJ"},{"key":"5035_CR2","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1161\/STROKEAHA.110.602615","volume":"42","author":"KM Mohan","year":"2011","unstructured":"Mohan\u00a0KM, Wolfe\u00a0CD, Rudd\u00a0AG et al (2011) Risk and cumulative risk of stroke recurrence: a\u00a0systematic review and meta-analysis. Stroke 42:1489\u20131494","journal-title":"Stroke"},{"key":"5035_CR3","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1056\/NEJMoa1802712","volume":"378","author":"P Amarenco","year":"2018","unstructured":"Amarenco\u00a0P, Lavallee\u00a0PC, Monteiro Tavares\u00a0L et al (2018) Five-year risk of stroke after TIA or minor ischemic stroke. N\u00a0Engl J Med 378:2182\u20132190","journal-title":"N Engl J Med"},{"key":"5035_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S0140-6736(07)61448-2","volume":"370","author":"PM Rothwell","year":"2007","unstructured":"Rothwell\u00a0PM, Giles\u00a0MF, Chandratheva\u00a0A et al (2007) Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a\u00a0prospective population-based sequential comparison. Lancet 370:1432\u20131442","journal-title":"Lancet"},{"key":"5035_CR5","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.jacc.2019.12.072","volume":"75","author":"HC Diener","year":"2020","unstructured":"Diener\u00a0HC, Hankey\u00a0GJ (2020) Primary and secondary prevention of Ischemic stroke and cerebral hemorrhage: JACC focus seminar. J\u00a0Am Coll Cardiol 75:1804\u20131818","journal-title":"J Am Coll Cardiol"},{"key":"5035_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","volume":"387","author":"X Xie","year":"2016","unstructured":"Xie\u00a0X, Atkins\u00a0E, Lv\u00a0J et al (2016) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387:435\u2013443","journal-title":"Lancet"},{"key":"5035_CR7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaneurol.2019.2167","volume":"76","author":"K Kitagawa","year":"2019","unstructured":"Kitagawa\u00a0K, Yamamoto\u00a0Y, Arima\u00a0H et al (2019) Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol 76:1309\u20131318","journal-title":"JAMA Neurol"},{"key":"5035_CR8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams\u00a0B, Mancia\u00a0G, Spiering\u00a0W et\u00a0al (2018) 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart\u00a0J 39:3021\u20133104","journal-title":"Eur Heart J"},{"key":"5035_CR9","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1212\/WNL.0000000000005023","volume":"90","author":"NE Andrew","year":"2018","unstructured":"Andrew\u00a0NE, Kim\u00a0J, Thrift\u00a0AG et\u00a0al (2018) Prescription of antihypertensive medication at discharge influences survival following stroke. Neurology 90:e745\u2013e753","journal-title":"Neurology"},{"key":"5035_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group (2002) MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a\u00a0randomised placebo-controlled trial. Lancet 360:7\u201322","journal-title":"Lancet"},{"key":"5035_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (Sparcl) Investigators","year":"2006","unstructured":"The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (Sparcl) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. N\u00a0Engl J Med 355:549\u2013559","journal-title":"N Engl J Med"},{"key":"5035_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000104474","volume":"24","author":"M Paciaroni","year":"2007","unstructured":"Paciaroni\u00a0M, Hennerici\u00a0M, Agnelli\u00a0G et\u00a0al (2007) Statins and stroke prevention. Cerebrovasc Dis 24:170\u2013182","journal-title":"Cerebrovasc Dis"},{"key":"5035_CR13","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1212\/01.wnl.0000296277.63350.77","volume":"70","author":"LB Goldstein","year":"2008","unstructured":"Goldstein\u00a0LB, Amarenco\u00a0P, Szarek\u00a0M et\u00a0al (2008) Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology 70:2364\u20132370","journal-title":"Neurology"},{"key":"5035_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/jnnp-2018-318483","volume":"90","author":"OJ Ziff","year":"2019","unstructured":"Ziff\u00a0OJ, Banerjee\u00a0G, Ambler\u00a0G et al (2019) Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J\u00a0Neurol Neurosurg Psychiatry 90:75\u201383","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5035_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","volume":"8","author":"P Amarenco","year":"2009","unstructured":"Amarenco\u00a0P, Labreuche\u00a0J (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8:453\u2013463","journal-title":"Lancet Neurol"},{"key":"5035_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1910355","volume":"382","author":"P Amarenco","year":"2020","unstructured":"Amarenco\u00a0P, Kim\u00a0JS, Labreuche\u00a0J et\u00a0al (2020) A comparison of two LDL cholesterol targets after ischemic stroke. N\u00a0Engl J Med 382:9","journal-title":"N Engl J Med"},{"key":"5035_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41:111\u2013188","journal-title":"Eur Heart J"},{"key":"5035_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine\u00a0MS, Giugliano\u00a0RP, Keech\u00a0AC et\u00a0al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N\u00a0Engl J Med 376:1713\u20131722","journal-title":"N Engl J Med"},{"key":"5035_CR19","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz\u00a0GG, Steg\u00a0PG, Szarek\u00a0M et\u00a0al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N\u00a0Engl J Med 379:2097\u20132107","journal-title":"N Engl J Med"},{"key":"5035_CR20","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray\u00a0KK, Seshasai\u00a0SR, Wijesuriya\u00a0S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a\u00a0meta-analysis of randomised controlled trials. Lancet 373:1765\u20131772","journal-title":"Lancet"},{"key":"5035_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","volume":"48","author":"M Lee","year":"2017","unstructured":"Lee\u00a0M, Saver\u00a0JL, Liao\u00a0HW et al (2017) Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke 48:388\u2013393","journal-title":"Stroke"},{"key":"5035_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/HCO.0000000000000673","volume":"34","author":"EJ North","year":"2019","unstructured":"North\u00a0EJ, Newman\u00a0JD (2019) Review of cardiovascular outcomes trials of sodium-glucose cotransporter\u20112 inhibitors and glucagon-like peptide\u20111 receptor agonists. Curr Opin Cardiol 34:687\u2013692","journal-title":"Curr Opin Cardiol"},{"key":"5035_CR23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1161\/STROKEAHA.119.027557","volume":"51","author":"G Bellastella","year":"2020","unstructured":"Bellastella\u00a0G, Maiorino\u00a0MI, Longo\u00a0M et al (2020) Glucagon-like peptide\u20111 receptor agonists and prevention of stroke systematic review of cardiovascular outcome trials with meta-analysis. Stroke 51:666\u2013669","journal-title":"Stroke"},{"key":"5035_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jama.291.5.565","volume":"291","author":"JF Toole","year":"2004","unstructured":"Toole\u00a0JF, Malinow\u00a0MR, Chambless\u00a0LE et\u00a0al (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 291:565\u2013575","journal-title":"JAMA"},{"key":"5035_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1474-4422(10)70187-3","volume":"9","author":"Vitatops Trial Study Group","year":"2010","unstructured":"Vitatops Trial Study Group (2010) B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a\u00a0randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 9:855\u2013865","journal-title":"Lancet Neurol"},{"key":"5035_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1474-4422(12)70091-1","volume":"11","author":"GJ Hankey","year":"2012","unstructured":"Hankey\u00a0GJ, Eikelboom\u00a0JW, Yi\u00a0Q et al (2012) Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a\u00a0post-hoc subanalysis of VITATOPS, a\u00a0randomised, placebo-controlled trial. Lancet Neurol 11:512\u2013520","journal-title":"Lancet Neurol"},{"key":"5035_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa010534","volume":"345","author":"CM Viscoli","year":"2001","unstructured":"Viscoli\u00a0CM, Brass\u00a0LM, Kernan\u00a0WN et al (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N\u00a0Engl J Med 345:1243\u20131249","journal-title":"N Engl J Med"},{"key":"5035_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"524","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 524:71\u201386","journal-title":"BMJ"},{"key":"5035_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","volume":"375","author":"SC Johnston","year":"2016","unstructured":"Johnston\u00a0SC, Amarenco\u00a0P, Albers\u00a0GW et\u00a0al (2016) Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N\u00a0Engl J Med 375:35\u201343","journal-title":"N Engl J Med"},{"key":"5035_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1474-4422(17)30038-8","volume":"16","author":"P Amarenco","year":"2017","unstructured":"Amarenco\u00a0P, Albers\u00a0GW, Denison\u00a0H et al (2017) Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a\u00a0subgroup analysis of SOCRATES, a\u00a0randomised, double-blind, controlled trial. Lancet Neurol 16:301\u2013310","journal-title":"Lancet Neurol"},{"key":"5035_CR31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","volume":"6","author":"J Kennedy","year":"2007","unstructured":"Kennedy\u00a0J, Hill\u00a0MD, Ryckborst\u00a0KJ et\u00a0al (2007) Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a\u00a0randomised controlled pilot trial. Lancet Neurol 6:961\u2013969","journal-title":"Lancet Neurol"},{"key":"5035_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","volume":"369","author":"Y Wang","year":"2013","unstructured":"Wang\u00a0Y, Wang\u00a0Y, Zhao\u00a0X et\u00a0al (2013) Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N\u00a0Engl J Med 369:11\u201319","journal-title":"N Engl J Med"},{"key":"5035_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","volume":"379","author":"SC Johnston","year":"2018","unstructured":"Johnston\u00a0SC, Easton\u00a0JD, Farrant\u00a0M et al (2018) Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N\u00a0Engl J Med 379:215\u2013225","journal-title":"N Engl J Med"},{"key":"5035_CR34","doi-asserted-by":"publisher","first-page":"k5130","DOI":"10.1136\/bmj.k5130","volume":"363","author":"K Prasad","year":"2018","unstructured":"Prasad\u00a0K, Siemieniuk\u00a0R, Hao\u00a0Q et\u00a0al (2018) Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a\u00a0clinical practice guideline. BMJ 363:k5130","journal-title":"BMJ"},{"key":"5035_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","volume":"383","author":"SC Johnston","year":"2020","unstructured":"Johnston\u00a0SC, Amarenco\u00a0P, Denison\u00a0H et\u00a0al (2020) Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N\u00a0Engl J Med 383:207\u2013217","journal-title":"N Engl J Med"},{"key":"5035_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/jnnp.66.2.255","volume":"65","author":"A Algra","year":"1999","unstructured":"Algra\u00a0A, van Gijn\u00a0J (1999) Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J\u00a0Neurol Neurosurg Psychiatry 65:255","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5035_CR37","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"Caprie Steering Committee","year":"1996","unstructured":"Caprie Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329\u20131339","journal-title":"Lancet"},{"key":"5035_CR38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","volume":"364","author":"HC Diener","year":"2004","unstructured":"Diener\u00a0HC, Bogousslavsky\u00a0J, Brass\u00a0LM et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364:331\u2013337","journal-title":"Lancet"},{"key":"5035_CR39","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt\u00a0DL, Fox\u00a0KA, Hacke\u00a0W et\u00a0al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N\u00a0Engl J Med 354:1706\u20131717","journal-title":"N Engl J Med"},{"key":"5035_CR40","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1056\/NEJMoa1204133","volume":"367","author":"OR Benavente","year":"2012","unstructured":"Benavente\u00a0OR, Hart\u00a0RG, Mcclure\u00a0LA et\u00a0al (2012) Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N\u00a0Engl J Med 367:817\u2013825","journal-title":"N Engl J Med"},{"key":"5035_CR41","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","volume":"342","author":"European Atrial Fibrillation Trial (Eaft) Study Group","year":"1993","unstructured":"European Atrial Fibrillation Trial (Eaft) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255\u20131262","journal-title":"Lancet"},{"key":"5035_CR42","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1161\/01.STR.0000129900.70583.67","volume":"35","author":"R Saxena","year":"2004","unstructured":"Saxena\u00a0R, Koudstaal\u00a0PJ (2004) Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a\u00a0history of stroke or transient ischemic attack. Stroke 35:1782\u20131783","journal-title":"Stroke"},{"key":"5035_CR43","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Connolly\u00a0S, Pogue\u00a0J, Hart\u00a0R et\u00a0al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a\u00a0randomised controlled trial. Lancet 367:1903\u20131912","journal-title":"Lancet"},{"key":"5035_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/1747493017700663","volume":"12","author":"G Ntaios","year":"2017","unstructured":"Ntaios\u00a0G, Papavasileiou\u00a0V, Diener\u00a0HC et al (2017) Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 12:589\u2013596","journal-title":"Int J Stroke"},{"key":"5035_CR45","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1161\/STROKEAHA.119.028118","volume":"51","author":"T Mizoguchi","year":"2020","unstructured":"Mizoguchi\u00a0T, Tanaka\u00a0K, Toyoda\u00a0K et al (2020) Early initiation of direct oral anticoagulants after onset of stroke and short- and long-term outcomes of patients with nonvalvular atrial fibrillation. Stroke 51:883\u2013891","journal-title":"Stroke"},{"key":"5035_CR46","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1160\/TH16-03-0217","volume":"116","author":"M Paciaroni","year":"2016","unstructured":"Paciaroni\u00a0M, Agnelli\u00a0G, Ageno\u00a0W et\u00a0al (2016) Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost 116:410\u2013416","journal-title":"Thromb Haemost"},{"key":"5035_CR47","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof\u00a0P, Benussi\u00a0S, Kotecha\u00a0D et\u00a0al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart\u00a0J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"5035_CR48","doi-asserted-by":"publisher","first-page":"I13","DOI":"10.1093\/eurheartj\/suaa104","volume":"22","author":"H-C Diener","year":"2020","unstructured":"Diener\u00a0H\u2011C, Hankey\u00a0GJ, Easton\u00a0JD et al (2020) Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 22:I13\u2013I21","journal-title":"Eur Heart J Suppl"},{"key":"5035_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","volume":"24","author":"HP Adams Jr.","year":"1993","unstructured":"Adams\u00a0HP Jr., Bendixen\u00a0BH, Kappelle\u00a0LJ et\u00a0al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a\u00a0multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 24:35\u201341","journal-title":"Stroke"},{"key":"5035_CR50","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","volume":"13","author":"RG Hart","year":"2014","unstructured":"Hart\u00a0RG, Diener\u00a0HC, Coutts\u00a0SB et\u00a0al (2014) Embolic strokes of undetermined source: the case for a\u00a0new clinical construct. Lancet Neurol 13:429\u2013438","journal-title":"Lancet Neurol"},{"key":"5035_CR51","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","volume":"380","author":"HC Diener","year":"2019","unstructured":"Diener\u00a0HC, Sacco\u00a0RL, Easton\u00a0JD et\u00a0al (2019) Dabigatran for prevention of stroke after embolic stroke of undetermined source. N\u00a0Engl J Med 380:1906\u20131917","journal-title":"N Engl J Med"},{"key":"5035_CR52","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","volume":"378","author":"RG Hart","year":"2018","unstructured":"Hart\u00a0RG, Sharma\u00a0M, Mundl\u00a0H et\u00a0al (2018) Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N\u00a0Engl J Med 378:2191\u20132201","journal-title":"N Engl J Med"},{"key":"5035_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0025-6196(12)60336-X","volume":"59","author":"PT Hagen","year":"1984","unstructured":"Hagen\u00a0PT, Scholz\u00a0DG, Edwards\u00a0WD (1984) Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 59:17\u201320","journal-title":"Mayo Clin Proc"},{"key":"5035_CR54","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","volume":"366","author":"AJ Furlan","year":"2012","unstructured":"Furlan\u00a0AJ, Reisman\u00a0M, Massaro\u00a0J et\u00a0al (2012) Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N\u00a0Engl J Med 366:991\u2013999","journal-title":"N Engl J Med"},{"key":"5035_CR55","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","volume":"368","author":"JD Carroll","year":"2013","unstructured":"Carroll\u00a0JD, Saver\u00a0JL, Thaler\u00a0DE et\u00a0al (2013) Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N\u00a0Engl J Med 368:1092\u20131100","journal-title":"N Engl J Med"},{"key":"5035_CR56","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","volume":"368","author":"B Meier","year":"2013","unstructured":"Meier\u00a0B, Kalesan\u00a0B, Mattle\u00a0HP et\u00a0al (2013) Percutaneous closure of patent foramen ovale in cryptogenic embolism. N\u00a0Engl J Med 368:1083\u20131091","journal-title":"N Engl J Med"},{"key":"5035_CR57","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","volume":"377","author":"JL Mas","year":"2017","unstructured":"Mas\u00a0JL, Derumeaux\u00a0G, Guillon\u00a0B et\u00a0al (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N\u00a0Engl J Med 377:1011\u20131021","journal-title":"N Engl J Med"},{"key":"5035_CR58","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","volume":"377","author":"JL Saver","year":"2017","unstructured":"Saver\u00a0JL, Carroll\u00a0JD, Thaler\u00a0DE et al (2017) Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N\u00a0Engl J Med 377:1022\u20131032","journal-title":"N Engl J Med"},{"key":"5035_CR59","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","volume":"377","author":"L Sondergaard","year":"2017","unstructured":"Sondergaard\u00a0L, Kasner\u00a0SE, Rhodes\u00a0JF et\u00a0al (2017) Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N\u00a0Engl J Med 377:1033\u20131042","journal-title":"N Engl J Med"},{"key":"5035_CR60","doi-asserted-by":"publisher","first-page":"e023761","DOI":"10.1136\/bmjopen-2018-023761","volume":"8","author":"H Mir","year":"2018","unstructured":"Mir\u00a0H, Siemieniuk\u00a0RAC, Ge\u00a0LC et al (2018) Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open 8:e23761","journal-title":"BMJ Open"},{"key":"5035_CR61","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00115-018-0609-y","volume":"89","author":"HC Diener","year":"2018","unstructured":"Diener\u00a0HC, Grau\u00a0AJ et\u00a0al (2018) Kryptogener Schlaganfall und offenes Formaen ovale: S2e Leitlinie. Nervenarzt 89:1143\u20131153","journal-title":"Nervenarzt"},{"key":"5035_CR62","first-page":"CD001081","volume":"6","author":"S Orrapin","year":"2017","unstructured":"Orrapin\u00a0S, Rerkasem\u00a0K (2017) Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev 6:CD1081","journal-title":"Cochrane Database Syst Rev"},{"key":"5035_CR63","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0140-6736(98)11415-0","volume":"353","author":"PM Rothwell","year":"1999","unstructured":"Rothwell\u00a0PM, Warlow\u00a0CP (1999) Prediction on benefit from carotid endarterectomy in individual patients: a\u00a0risk-modelling study. Lancet 353:2105\u20132110","journal-title":"Lancet"},{"key":"5035_CR64","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(14)61184-3","volume":"385","author":"LH Bonati","year":"2015","unstructured":"Bonati\u00a0LH, Dobson\u00a0J, Featherstone\u00a0RL et al (2015) Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the international carotid stenting study (ICSS) randomised trial. Lancet 385:529\u2013538","journal-title":"Lancet"},{"key":"5035_CR65","first-page":"CD000515","volume":"9","author":"LH Bonati","year":"2012","unstructured":"Bonati\u00a0LH, Lyrer\u00a0P, Ederle\u00a0J et\u00a0al (2012) Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 9:CD515","journal-title":"Cochrane Database Syst Rev"},{"key":"5035_CR66","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa1505215","volume":"374","author":"TG Brott","year":"2016","unstructured":"Brott\u00a0TG, Howard\u00a0G, Roubin\u00a0GS et al (2016) Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N\u00a0Engl J Med 374:1021\u20131031","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05035-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-021-05035-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05035-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T06:04:18Z","timestamp":1675231458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-021-05035-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5035"],"URL":"https:\/\/doi.org\/10.1007\/s00059-021-05035-0","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"25 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>H.C.\u00a0Diener<\/b> hat in den letzten 3\u00a0Jahren Honorare f\u00fcr Teilnahme an klinischen Studien, Mitarbeit in Advisory Boards und Vortr\u00e4ge erhalten von: Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Novartis, Pfizer, Portola, Sanofi-Aventis und Servier. Er hat Forschungsmittel von den folgenden Institutionen erhalten: DFG, BMBF, EU, NIH, EAST-AFnet und Heinz-Nixdorf-Stiftung. H.C. Diener war beteiligt an der Erstellung von Leitlinien der DGN, der DSG, der ESC und EHRA.<b> G.\u00a0Nickenig<\/b> hat Honorare erhalten f\u00fcr Vortr\u00e4ge oder Advisory Bords von Abbott, AstraZeneca, Bayer, Berlin Chemie, Biosensus, Biotronic, BMS, Boehringer Ingelheim, Cardiovalve, Daiichi Sankyo, Edwards, Medtronic, Novartis, Pfizer, Sanofi-Aventis. Er besitzt Stock Options von Beren und Cardiovalve. Er hat teilgenommen an klinischen Studien von Abbott, AstraZeneca, Bayer, Berlin Chemie, Biosensus, Biotronic, BMS, Boehringer Ingelheim, Cardiovalve, Daiichi Sankyo, Edwards, Medtronic, Novartis, Pfizer, Sanofi-Aventis. Forschungsf\u00f6rderung von DFG, BMBF, EU, Abbott, Bayer, BMS, Boehringer Ingelheim, Edwards, Medtronic, Novartis, Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}